Core Viewpoint - Fosun United Health has successfully completed a strategic capital increase of 810 million RMB, marking a significant milestone in its capital strength, shareholder structure, and solvency capabilities [1][4]. Group 1: Capital Increase Details - The total amount of the capital increase is 810 million RMB, raising the registered capital from 694.44 million RMB to 1.01085 billion RMB [1]. - The capital increase involves the issuance of 31,641,000 new shares at a price of 2.56 RMB per share [1]. - The new shareholders include the International Finance Corporation (IFC) and the Asian Development Bank (ADB), alongside existing shareholder Fosun Pharma, each subscribing to 10,547,000 shares [1][3]. Group 2: Shareholder Structure Changes - Prior to the capital increase, Fosun Industrial held 14.4% of the shares, making it the largest shareholder, while Fosun Pharma and Nansha KJ held 14% each, ranking third [2]. - Post-increase, Fosun Pharma's shareholding rose to 20.05%, making it the largest shareholder, while IFC and ADB each hold 10.43%, becoming the second-largest shareholders [2][3]. - The total shareholding of the Fosun group increased slightly from 28.4% to 29.94% after the capital increase [2]. Group 3: Business Performance and Future Plans - Since its inception, Fosun United Health has seen a continuous increase in premium income, achieving 5.226 billion RMB in insurance revenue in 2024, a 27% year-on-year increase, with a net profit of 40 million RMB, up over 80% [5]. - The company plans to leverage the resources of its shareholders to expand its product offerings and enhance service experiences, focusing on critical areas such as major diseases and chronic disease management [6]. - Following the capital increase, the solvency pressure is expected to ease, with core solvency ratios projected to reach 117% and comprehensive solvency ratios at 173% by the end of 2024 [6].

Group 1 - The core point of the article is that Fosun United Health Insurance has received approval from the Guangdong Regulatory Bureau of the National Financial Supervisory Administration for a capital increase, with new shareholders including the International Finance Corporation (IFC) and the Asian Development Bank (ADB) [1] - The total amount of the capital increase is 810 million yuan, raising the registered capital of Fosun United Health Insurance from 694.44 million yuan to 1.01085 billion yuan [1] - Existing shareholder Fosun Pharma continues to increase its stake in the company as part of this capital increase [1]

Core Viewpoint - The article emphasizes the journey and vision of Fosun Pharma under the leadership of Chairman Chen Yuqing, focusing on innovation, global expansion, and the integration of AI in drug development and operations [3][10][20]. Group 1: Company Background and Leadership - Chen Yuqing transitioned from academia to the corporate world 26 years ago, eventually becoming the Chairman of Fosun Pharma in April 2025 [1][3]. - Under his leadership, Fosun Pharma has grown into a nearly 100 billion yuan global innovative pharmaceutical company, with a strong emphasis on corporate culture that fosters innovation and talent development [3][4]. Group 2: Innovation and Product Development - Fosun Pharma has consistently prioritized innovation, launching 12 innovative drugs since 2019, including the first CAR-T product in China and the first PD-1 monoclonal antibody approved for small cell lung cancer [4][6]. - The company’s innovative drug revenue exceeded 4.3 billion yuan in the first half of 2025, accounting for 31% of its pharmaceutical business revenue, with a year-on-year growth of 14.26% [8][10]. Group 3: Globalization Strategy - Fosun Pharma's globalization strategy focuses on building local capabilities rather than merely exporting products, with over 1,000 personnel in its overseas commercialization team and a marketing network covering over 110 countries [10][12]. - The company has established regional distribution centers in emerging markets and has supplied over 420 million doses of anti-malarial products globally, significantly impacting public health [13][20]. Group 4: AI Integration in Operations - Fosun Pharma is actively integrating AI into its operations, utilizing the PharmAID decision-making platform to enhance drug development efficiency, reducing target validation time by over 60% [14][15]. - The company emphasizes that while AI is a powerful tool for enhancing efficiency, it cannot replace the intrinsic value of human expertise and understanding of patient needs [16][17]. Group 5: Future Vision and Commitment - The company aims to become a global "Big Pharma" over the next decade, focusing on innovation, deep internationalization, and comprehensive AI adoption as its core strategies [19][20]. - Fosun Pharma's mission remains to ensure every family enjoys health, reflecting its commitment to addressing clinical needs through continuous innovation [20].

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the European Commission for its subsidiaries' biosimilar products BILDYOSR and BILPREVDAR, which are based on denosumab [2][3] - The approval allows these products to be marketed in all EU member states as well as Iceland, Liechtenstein, and Norway [2] Product Information - HLX14, the biosimilar denosumab, is intended for the treatment of osteoporosis in postmenopausal women at high risk of fractures, along with other indications aligned with the reference products Prolia and XGEVA [2] - The cumulative R&D investment for HLX14 is approximately RMB 323 million as of July 2025 [4] Market Impact - The approval in the EU follows a previous approval in the US, enhancing the company's international market presence [5] - The global sales of denosumab injection products are projected to be approximately USD 7.463 billion in 2024 [4] - Commercial rights for HLX14 outside of China were granted to Organon LLC in June 2022, allowing for milestone and sales commission rights following the EU approval [5]

Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 12,500 shares on September 19, 2025, indicating a trend of net selling over the past 20 trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, there were 3 days of net buying by southbound funds, totaling an increase of 744,400 shares [1] - Over the past 20 trading days, southbound funds have reduced their holdings on 15 days, with a total net reduction of 25,690,700 shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2: Trading Data - On September 19, 2025, the total number of shares held was 321 million, with a change of -12,500 shares, reflecting a change of -0.00% [2] - On September 18, 2025, the total number of shares held was 321 million, with an increase of 1,714,000 shares, reflecting a change of 0.54% [2] - On September 17, 2025, the total number of shares held was 261 million, with a decrease of 4,086,000 shares, reflecting a change of -1.27% [2] Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2] - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]

Group 1 - Juewei Foods faces risk warning and will be labeled as "ST Juewei" due to disclosure violations, with trading suspension on September 22, 2025 [2] - Fosun Pharma's subsidiary has received EU approval for its osteoporosis treatment products, with projected global sales of approximately $7.463 billion in 2024 [3] - Tailin Microelectronics has achieved mass production of its edge AI chips, with sales reaching millions of RMB in Q2 2025 [3] Group 2 - Saiseng Pharma's major shareholder plans to reduce their stake by up to 2% within three months [4] - Zhongcheng Group's stake in Zhongcheng Co. has increased to 42.12% after transferring shares to Zhongji Import and Export [5] - Dingsheng Co. plans to transfer 4.82% of its shares through an inquiry-based method [6] Group 3 - Fudan Fuhua will be labeled as "ST Fuhua" starting September 23, 2025, due to regulatory warnings [7] - Huadian Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [8] - New Jufeng's shareholders plan to reduce their stake by up to 4.5% [9] Group 4 - Watson Bio's subsidiary has received acceptance for clinical trials of its mRNA vaccine for shingles [10] - Jintou Chengkai is adjusting its major asset restructuring plan, which will not change the controlling shareholder [11] - Hangdian Co. has seen a significant stock price increase of 46.52% over four trading days, raising concerns about potential volatility [12] Group 5 - Shenli Co. plans to reduce its stake by up to 3% due to funding needs [13] - Xinwangda's subsidiary is investing 60 million RMB to establish a private equity fund focused on energy storage projects [14] - Fuxai Technology has set an initial transfer price of 72.08 RMB per share for its inquiry-based transfer [15] Group 6 - Jilin Aodong's subsidiary has received a drug registration certificate for a traditional Chinese medicine [16] - Tianpu Co. has experienced a 13-day stock price surge, raising concerns about potential rapid declines [17] - Zhongchu Co. is increasing its investment in Zhongchu Hengke by 84.3146 million RMB through debt-to-equity swaps [18] Group 7 - Wuzhou Transportation's major shareholder has secured a loan commitment of up to 153 million RMB for share buybacks [19] - Shanxi Fenjiu has elected a new chairman and vice-chairmen for its board [20] - Qujiang Cultural Tourism has confirmed normal operations amid stock price fluctuations [21] Group 8 - Sike Rui will be labeled as "ST Sike Rui" and suspended for one day due to regulatory warnings [22] - Anning Co. is applying for a 3 billion RMB syndicated loan for asset restructuring [23] - Anning Co. has completed a significant debt restructuring plan totaling approximately 192.669 billion RMB [27] Group 9 - China Chemical reported a total contract amount of 256.339 billion RMB from January to August 2025 [28] - Jishi Media has elected a new chairman [29] - Lingyun Optics has adjusted its share repurchase price limit to 52 RMB per share [30] Group 10 - Baoli International plans to invest in semiconductor testing equipment company Hongtai Technology [29] - Pinming Technology's stock will continue to be suspended for up to three additional trading days [30] - Ankai Micro plans to invest 20 million RMB for a 4% stake in Shiqi Future [30]

（文章来源：证券日报） 本报讯天眼查App显示，近日，复星凯瑞（深圳）生物科技有限公司成立，法定代表人为陈星蓉，注册 资本1亿元，经营范围含医学研究和试验发展、工程和技术研究和试验发展、细胞技术研发和应用、人 体干细胞技术开发和应用、人体基因诊断与治疗技术开发、专用化学产品销售、仪器仪表销售等。股东 信息显示，该公司由复星医药旗下复星凯瑞（上海）生物科技有限公司全资持股。 ...

Group 1 - The core point of the news is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA®, in the European Union and certain EEA countries [1][2] Group 2 - The biosimilar HLX14 is developed for the treatment of osteoporosis in postmenopausal women at high risk of fractures, along with other indications consistent with the reference drug label [2] - The product is expected to receive approval in the United States by August 2025 for eight indications related to osteoporosis treatment, covering all indications approved for the reference product in the U.S. [2] - As of July 2025, the cumulative R&D investment for HLX14 is approximately RMB 323 million (unaudited) [2]

Group 1 - The core point of the news is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the European Commission for the marketing authorization applications (MAAs) of two biosimilar products, BILDYOS® and BILPREVDA®, in the European Union and certain EEA countries [1][2] Group 2 - The biosimilar HLX14 is developed for the treatment of osteoporosis in postmenopausal women at high risk of fractures, along with other indications consistent with the reference drug label [2] - The product is expected to receive approval in the United States by August 2025 for eight indications related to osteoporosis treatment, covering all indications approved for the reference product in the U.S. [2] - As of July 2025, the cumulative R&D investment for HLX14 is approximately RMB 323 million (unaudited) [2]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （股份代號：02196） 海外監管公告 证券代码：600196 股票简称：复星医药 编号：临 2025-149 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲歐盟註冊批准的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年9 月1 9 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先 ...